| |
Newsroom /
Health and Fitness
/
Healthcare
/
Musculoskeletal Disorders Therapeutics to 2016
Musculoskeletal Disorders Therapeutics to 2016 
The High Growth Rate and Increasing Use of Biologics Has Made the Musculoskeletal Disorders Therapeutics Market Attractive
Hyderabad,
AP,
India
(prbd.net)
20/09/2010
"- Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options In Osteoporosis and Rheumatoid Arthritis
"
The global musculoskeletal disorders therapeutics market is a fast growing market with such disorders considered to be the prime factor for chronic disability in the workforce. In 2009, the market was valued at $26.8 billion and is forecasted to grow to $45.4 billion in 2016 showing a growth rate of 8% between 2009 and 2016. According to the Orthopedic Industry Report, in 2006 the prevalence of musculoskeletal disorder was 25 percent more than it was in 1996. Consequently the market has been growing at a fast pace in the past years which is expected to accelerate in the coming years. However, the market will face a marginal decline in revenues due to the patent expiries of the prominent selling drugs such as Boniva, Celebrex, Voltaren, Humira between the years 2009 and 2016. This decline in the market will be undermined by the launch of blockbuster drugs such as drugs like Prolia, Vicodin and Ipex; summed up with the presence of many potential biologics in the late stage of drug development stage. In addition, the increase in incidence rates of osteoarthritis and rheumatoid arthritis will also trigger growth in the global musculoskeletal disorders therapeutics market. As a result, the market will continue to remain a fast growing one thereby attracting the activities of major pharmaceutical companies
For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=The-Musculoskeletal-Disorders-Therapeutics-Market-to-2016-Strong-Pipeline-Will-Drive-the-Rheumatoid-Arthritis-and-Osteoporosis-Market&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare
The musculoskeletal disorders therapeutics market has a strong pipeline base that will support the growth of this market thereby attracting many pharmaceutical and biotechnological companies. Major pharmaceutical companies such as Pfizer, Amgen, Merck, Roche, and Novartis are active in their pipeline for musculoskeletal disorders. One of the major activities is the development of biologics as a part of new treatment options. There are also some disease modifiers in the pipeline of osteoarthritis that are expected to enter the market in 2018. The entry of these disease modifiers will boost the osteoarthritis therapeutics market thereby bringing further growth to the musculoskeletal disorders therapeutics market in the coming years. The rapid entry of new players will add up to the competition of the existing players of this market. Hence, the presence of a highly active pipeline shows there will be strong competition in the musculoskeletal disorders therapeutics market in the coming years.
GBI Research, the leading business intelligence provider, has released its latest research, “Musculoskeletal Disorders Therapeutics to 2016 - Introduction of Monoclonal Antibodies with First - in - class Mechanism of Action to Increase Treatment Options In Osteoporosis and Rheumatoid Arthritis”. It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global musculoskeletal disorders therapeutics market. The report analyzes the markets for musculoskeletal disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, and price are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=The-Musculoskeletal-Disorders-Therapeutics-Market-to-2016-Strong-Pipeline-Will-Drive-the-Rheumatoid-Arthritis-and-Osteoporosis-Market&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare
Visit our report store: http://www.gbiresearch.com
For more details contact:
pressreleases@gbiresearch.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|